TY - JOUR
T1 - Solid organ transplantation after hematopoietic stem cell transplantation in childhood
T2 - A multicentric retrospective survey
AU - Faraci, Maura
AU - Bertaina, Alice
AU - Dalissier, Arnaud
AU - Ifversen, Marianne
AU - Schulz, Ansgar
AU - Gennery, Andrew
AU - Burkhardt, Birgit
AU - Badell Serra, Isabel
AU - Diaz-de-Heredia, Cristina
AU - Lanino, Edoardo
AU - Lankester, Arjan C.
AU - Gruhn, Bernd
AU - Matthes-Martin, Susanne
AU - Kühl, Joern S.
AU - Varotto, Stefania
AU - Paillard, Catherine
AU - Guilmatre, Audrey
AU - Sastre, Ana
AU - Abecasis, Manuel
AU - Garwer, Birgit
AU - Sedlacek, Petr
AU - Boelens, Jaap J.
AU - Beohou, Eric
AU - Bader, Peter
N1 - © 2018 The American Society of Transplantation and the American Society of Transplant Surgeons.
PY - 2019/6/1
Y1 - 2019/6/1
N2 - We report data obtained from a retrospective multicenter pediatric survey on behalf of the European Society for Blood and Marrow Transplantation (EBMT). Information on solid organ transplantation (SOT) performed in pediatric recipients of either autologous or allogeneic hematopoietic stem cell transplantation (HSCT) between 1984 and 2016 was collected in 20 pediatric EBMT Centers (25.6%). Overall, we evaluated data on 44 SOTs following HSCT including 20 liver (LTx), 12 lung (LuTx), 6 heart (HTx), and 6 kidney (KTx) transplantations. The indication for SOT was organ failure related to intractable graft-vs-host disease in 16 children (36.3%), acute or chronic HSCT-related toxicity in 18 (40.9%), and organ dysfunction related to the underlying disease in 10 (22.8%). The median follow-up was 10.9 years (95% confidence interval: 1.7-29.5). The overall survival rate at 1 and 5 years after SOT was 85.7% and 80.4%, respectively: it was 74% and 63.2% after LTx, 83.2% after HTx, and 100% equally after LuTx and KTx. This multicenter survey confirms that SOT represents a promising option in children with severe organ failure occurring after HSCT. Additional studies are needed to further establish the effectiveness of SOT after HSCT and to better understand the mechanism underlying this encouraging success.
AB - We report data obtained from a retrospective multicenter pediatric survey on behalf of the European Society for Blood and Marrow Transplantation (EBMT). Information on solid organ transplantation (SOT) performed in pediatric recipients of either autologous or allogeneic hematopoietic stem cell transplantation (HSCT) between 1984 and 2016 was collected in 20 pediatric EBMT Centers (25.6%). Overall, we evaluated data on 44 SOTs following HSCT including 20 liver (LTx), 12 lung (LuTx), 6 heart (HTx), and 6 kidney (KTx) transplantations. The indication for SOT was organ failure related to intractable graft-vs-host disease in 16 children (36.3%), acute or chronic HSCT-related toxicity in 18 (40.9%), and organ dysfunction related to the underlying disease in 10 (22.8%). The median follow-up was 10.9 years (95% confidence interval: 1.7-29.5). The overall survival rate at 1 and 5 years after SOT was 85.7% and 80.4%, respectively: it was 74% and 63.2% after LTx, 83.2% after HTx, and 100% equally after LuTx and KTx. This multicenter survey confirms that SOT represents a promising option in children with severe organ failure occurring after HSCT. Additional studies are needed to further establish the effectiveness of SOT after HSCT and to better understand the mechanism underlying this encouraging success.
KW - bone marrow/hematopoietic stem cell transplantation
KW - clinical research/practice
KW - graft-vs-host disease (GVHD)
KW - heart failure/injury
KW - kidney failure/injury
KW - liver disease
KW - lung (allograft) function/dysfunction
KW - organ transplantation in general
KW - pediatrics
UR - http://www.scopus.com/inward/record.url?scp=85060755879&partnerID=8YFLogxK
U2 - 10.1111/ajt.15240
DO - 10.1111/ajt.15240
M3 - Article
C2 - 30586230
AN - SCOPUS:85060755879
SN - 1600-6135
VL - 19
SP - 1798
EP - 1805
JO - American Journal of Transplantation
JF - American Journal of Transplantation
IS - 6
ER -